Women With Polycystic Ovary Syndrome (PCOS)
Açar sözlər
Mücərrəd
Təsvir
Will be performed case-control study with women with Polycystic Ovary Syndrome, according to the Rotterdam criteria and body mass index between 18 to 29.9. The control group will consist of women without Polycystic Ovary Syndrome, with a body mass index of 18 to 29.9 and no other comorbidities. In both groups collect anthropometric data such as age, weight, height, waist circumference and blood pressure. Exams will be requested: metabolic profile (total cholesterol (mg/dL) and fractions, triglycerides (mg/dL), blood count, liver function (U/L) and classical glycemic index (mg/dL); hormonal profile - insulin (uIU/ml), luteinizing hormone (IU/L), follicle stimulating hormone (IU/L), thyreostimulating hormone (uIU/ML), total and free testosterone (ng/ml), 17-hydroxyprogesterone (ng/ml), dehydroepiandrosterone (ng/ml), prolactin (ug/ml). Body composition (BMI) will be performed by absorption technique of two low energy beams emitted by X-ray - full body densitometry (DEXA). Expected result: To evaluate visceral fat and truncal of patients with diagnosis of Polycystic Ovary Syndrome without obesity.
Tarixlər
Son Doğrulandı: | 02/28/2017 |
İlk təqdim: | 03/24/2015 |
Təxmini qeydiyyat təqdim edildi: | 06/06/2015 |
İlk Göndərmə: | 06/09/2015 |
Son Yeniləmə Göndərildi: | 03/16/2017 |
Son Yeniləmə Göndərildi: | 03/19/2017 |
Həqiqi Təhsilin Başlama Tarixi: | 12/31/2013 |
Təxmini İlkin Tamamlanma Tarixi: | 08/31/2017 |
Təxmini İşin Tamamlanma Tarixi: | 11/30/2017 |
Vəziyyət və ya xəstəlik
Faza
Uyğunluq Kriteriyaları
Təhsil üçün uyğun yaşlar | 12 Years Üçün 12 Years |
Təhsilə Uyğun Cinslər | Female |
Nümunə götürmə metodu | Probability Sample |
Sağlam Könüllüləri qəbul edir | Bəli |
Kriteriyalar | Inclusion Criteria: - Polycystic Ovary Syndrome , body mass index of 18 to 29.9, without contraceptive use. Exclusion Criteria: - Hypothyroidism, hyperprolactinaemia (defined as serum prolactin levels greater than 25 ng/mL) - Cushing's syndrome - Nonclassical congenital adrenal hyperplasia (defined as serum 17-hydroxyprogesterone levels greater than 1.2 and 5.2 ng/mL in the follicular and luteal phase, respectively) and current or previous (within the last three months) use of oral contraceptives and other hormonal - Antidiabetic and antiobesity drugs. |
Nəticə
İlkin nəticə tədbirləri
1. Metabolic profile [12 months]
İkincili Nəticə Tədbirləri
1. Classical glycemic index [12 months]
2. Liver function [12 months]
3. luteinizing hormone [12 months]
4. Hormonal profile - insulin [12 months]
5. Follicle stimulating hormone [12 months]
6. thyreostimulating hormone [12 months]
7. Total and free testosterone [12 months]
8. 17-hydroxyprogesterone [12 months]
9. Dehydroepiandrosterone [12 months]
10. Prolactin [12 months]
11. DEXA [12 months]